J. Kevin Buchi
Non-Executive Director
Nanoscience and Nanotechnology
Benitec Biopharma
Australia
Biography
Mr. Buchi currently serves as the CEO of TetraLogic Pharmaceuticals a public U.S. Biotechnology company. Prior to that, Kevin served as Chief Executive Officer (‘CEO’) of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (‘Teva’) in October 2011. After the acquisition he served as Corporate Vice President, Global Branded Products of Teva. Kevin joined Cephalon, Inc. in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.
Research Interest
Nanoscience and Nanotechnology
